🔥Telegram İfşa

Strata Oncology will present new data in four scientific posters at the upcoming American Association for Cancer Research Annual Meeting #AACR23 Read more: bit.ly/41diMa0

CMO Scott Tomlins sat down with Inside Precision Medicine to discuss why researchers are focused on biomarker discovery to unlock the potential of immunotherapy - a trend he notes will "pave the way toward giving more patients the hope of an actual cure." More here: insideprecisionmedicine.com/topics/oncolog…

If you're at #AACR23, be sure to check out our posters! Abstract numbers and links in press release linked below. Have a great meeting!

Announcing Strata Select, a first-of-its-kind molecular profiling for patients with advanced cancer. This marks a significant milestone in our pursuit to deliver precision immunotherapy and empower oncologists to make better-informed treatment decisions. bit.ly/3H6q7Rq

We're proud to be on the list for Fast Company's World Changing Ideas Awards for the second year in a row, this time for the Immunotherapy Response Score! Learn more: bit.ly/3VouTzo #FCWorldChangingIdeas

Connect with us this weekend at #ASCO23 to learn more about Strata Select, including new data just published in an ASCO abstract -- an independent validation of the Immunotherapy Response Score conducted by Kaiser Permanente. meetings.asco.org/abstracts-pres…

We’re excited to be in Chicago for #ASCO23! Be sure to stop by booth #24081 to talk with our team about #PrecisionOncology, #Immunotherapy and the recently launched Strata Select test

At #ASCO23? Be sure to visit Strata Oncology at booth ##24081 to learn more about Strata Select, a pan-solid tumor molecular profiling test for patients with advanced cancer that provides treatment selection guidance for #immunotherapy and beyond #PrecisionOncology #Biomarkers

Strata Select helps you make a critical treatment decision for your patients with advanced cancer – whether or not to treat with anti-PD-1/PD-L1 #immunotherapy and, if so, whether to prescribe monotherapy or combination therapy Learn more at #ASCO23 booth #24081

Another year, another ASCO meeting, another amazing opportunity to connect with the #PrecisionOncology community to bond over our shared goal of ensuring every patient with cancer gets their best possible therapy See you next year! Goodbye #ASCO23!

Dr. Sachdev Thomas of Kaiser Permanente spoke with OncLive.com about the independent validation of Strata's #Immunotherapy Response Score that his team conducted onclive.com/view/dr-thomas…

Strata Oncology is excited to announce the publication of a new study adding to the clinical utility of our innovative Immunotherapy Response Score, which is available as part of the Strata Select molecular profiling test. Read the latest results in Cancer Research Communications!

Read about how the Immunotherapy Response Score can help guide critical immunotherapy decisions for patients with advanced cancer in a recent article by our co-founder and Chief Medical Officer Scott Tomlins linkedin.com/pulse/immunoth…

Strata Oncology is excited to announce new data supporting the utility of the Immunotherapy Response Score to guide informed clinical decisions for first-line treatment of patients with #NSCLC, to be presented at #WCLC23, hosted by IASLC  bit.ly/3EuOoyC

In Boston for LSX Leaders USA Congress? Catch Strata Oncology Chief Business Development, Legal and Compliance Officer Catherine Sazdanoff on the "Future of Oncology Pharmaceutical Partnerships" panel with speakers from GSK, Astellas Pharma US and Servier Pharmaceuticals

Congrats to Scott Tomlins on being a 2023 PharmaVoice 100 honoree! Thank you for your endless commitment to improving the lives of patients with cancer. View his profile here: bit.ly/3PIvZES

We’re thrilled to announce that Goz Alhir has joined Strata Oncology as SVP, Commercialization. He brings a wealth of experience and an unrelenting dedication to improving patients' lives to the team. Read more:bit.ly/3M0d4DB

Strata CEO Dan Rhodes sat down with Clinical Lab Products Magazine to discuss the promise and challenges facing precision oncology clpmag.com/diagnostic-tec…

Strata is honored to be this year's "Diagnostics Innovation of the Year" award by BioTech Breakthrough! This award is in recognition of Strata Select, our first-of-its-kind pan-solid tumor molecular profiling solution for patients with advanced cancer. Learn more:

Strata Oncology will present new data on its innovative, proprietary biomarkers at #NACLC23 and #SABCS23 Read more: bit.ly/3R236D7 #lungcancer #NSCLC #breastcancer #biomarkers #immunotherapy #AntibodyDrugConjugates